144 related articles for article (PubMed ID: 33807822)
1. High Acceptability of an Orally Dispersible Tablet Formulation by Children.
Wagner-Hattler L; Kiene K; Bielicki J; Pfister M; Puchkov M; Huwyler J
Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33807822
[TBL] [Abstract][Full Text] [Related]
2. A survey of caregivers of Nigerian children less than 6 years of age to determine the experience and perception of acceptability of oral solid dosage forms.
Orubu S; Okwelogu C; Opanuga O; Tuleu C
Int J Pharm; 2018 Feb; 536(2):582-589. PubMed ID: 29100913
[TBL] [Abstract][Full Text] [Related]
3. Age-Appropriate Pediatric Dosage Forms in Japan: Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation.
Saito J; Akabane M; Komura M; Nakamura H; Ishikawa Y
Ther Innov Regul Sci; 2019 Jul; 53(4):455-471. PubMed ID: 30157669
[TBL] [Abstract][Full Text] [Related]
4. Meeting Challenges of Pediatric Drug Delivery: The Potential of Orally Fast Disintegrating Tablets for Infants and Children.
Golhen K; Buettcher M; Kost J; Huwyler J; Pfister M
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111519
[TBL] [Abstract][Full Text] [Related]
5. Can children swallow tablets? Outcome data from a feasibility study to assess the acceptability of different-sized placebo tablets in children (creating acceptable tablets (CAT)).
Bracken L; McDonough E; Ashleigh S; Wilson F; Shakeshaft J; Ohia U; Mistry P; Jones H; Kanji N; Liu F; Peak M
BMJ Open; 2020 Oct; 10(10):e036508. PubMed ID: 33039988
[TBL] [Abstract][Full Text] [Related]
6. Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment.
Wademan DT; Draper HR; Purchase SE; Palmer M; Hesseling AC; Van der Laan L; Garcia-Prats AJ
IJTLD Open; 2024 Feb; 1(2):69-75. PubMed ID: 38966689
[TBL] [Abstract][Full Text] [Related]
7. [Oral dosage forms for children: acceptability and palatability].
Kojima J
Yakugaku Zasshi; 2015; 135(2):245-7. PubMed ID: 25747220
[TBL] [Abstract][Full Text] [Related]
8. Acceptability of and adherence to dispersible zinc tablet in the treatment of acute childhood diarrhoea.
Nasrin D; Larson CP; Sultana S; Khan TU
J Health Popul Nutr; 2005 Sep; 23(3):215-21. PubMed ID: 16262017
[TBL] [Abstract][Full Text] [Related]
9. Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trial.
Münch J; Meissner T; Mayatepek E; Wargenau M; Breitkreutz J; Bosse HM; Klingmann V
Eur J Pharm Biopharm; 2021 Sep; 166():126-134. PubMed ID: 34153451
[TBL] [Abstract][Full Text] [Related]
10. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.
Chandrasekaran P; Kandasamy R
AAPS PharmSciTech; 2017 Aug; 18(6):1972-1986. PubMed ID: 27921260
[TBL] [Abstract][Full Text] [Related]
11. Creating Acceptable Tablets 3D (CAT 3D): A Feasibility Study to Evaluate the Acceptability of 3D Printed Tablets in Children and Young People.
Bracken L; Habashy R; McDonough E; Wilson F; Shakeshaft J; Ohia U; Garcia-Sorribes T; Isreb A; Alhnan MA; Peak M
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335892
[TBL] [Abstract][Full Text] [Related]
12. Acceptability of Prednisolone in an Open-Label Randomised Cross-Over Study-Focus on Formulation in Children.
Haslund-Krog SS; Jørgensen IM; Dalhoff K; Holst H
Children (Basel); 2022 Aug; 9(8):. PubMed ID: 36010126
[TBL] [Abstract][Full Text] [Related]
13. Co-Processed Excipients for Dispersible Tablets-Part 2: Patient Acceptability.
Dziemidowicz K; Lopez FL; Bowles BJ; Edwards AJ; Ernest TB; Orlu M; Tuleu C
AAPS PharmSciTech; 2018 Aug; 19(6):2646-2657. PubMed ID: 29943280
[TBL] [Abstract][Full Text] [Related]
14. Young patients' involvement in a composite endpoint method development on acceptability for paediatric oral dosage forms.
Reidemeister S; Nafria Escalera B; Marín D; Balayla J; Klingmann I; Klingmann V
Res Involv Engagem; 2023 Nov; 9(1):108. PubMed ID: 38031172
[TBL] [Abstract][Full Text] [Related]
15. Methods of administering oral formulations and child acceptability.
van Riet-Nales DA; Ferreira JA; Schobben AF; de Neef BJ; Egberts TC; Rademaker CM
Int J Pharm; 2015 Aug; 491(1-2):261-7. PubMed ID: 26143234
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007.
Strickley RG
J Pharm Sci; 2019 Apr; 108(4):1335-1365. PubMed ID: 30447227
[TBL] [Abstract][Full Text] [Related]
17. Acceptability of different oral formulations in infants and preschool children.
van Riet-Nales DA; de Neef BJ; Schobben AF; Ferreira JA; Egberts TC; Rademaker CM
Arch Dis Child; 2013 Sep; 98(9):725-31. PubMed ID: 23853004
[TBL] [Abstract][Full Text] [Related]
18. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the Acceptability, Swallowability, and Palatability of Film-Coated Mini-Tablet Formulation in Young Children: Results from an Open-Label, Single-Dose, Cross-Over Study.
Münch J; Sessler I; Bosse HM; Wargenau M; Dreesen JD; Loforese G; Webb NJA; Sivasubramanian R; Reidemeister S; Lustenberger P; Klingmann V
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376177
[TBL] [Abstract][Full Text] [Related]
20. Acceptability of oral solid medicines in older adults with and without dysphagia: A nested pilot validation questionnaire based observational study.
Liu F; Ghaffur A; Bains J; Hamdy S
Int J Pharm; 2016 Oct; 512(2):374-381. PubMed ID: 26970368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
